COMBI-AD is a randomised, double-blind, placebo-controlled, phase 3 trial comparing dabrafenib 150mg orally twice daily plus trametinib 2mg orally once daily versus two matched placebos. Study participants were at least 18 years of age and underwent complete resection of stage...
A prespecified exploratory biomarker analysis aimed to evaluate potential prognostic or predictive factors and mechanisms of resistance to adjuvant targeted
